P329G-engager: a universal mix &amp; match antibody-based adaptor platform for cancer immunotherapy
Year: 2025
Type: article
Language: en
Topic: Monoclonal and Polyclonal Antibodies Research
Authors and affiliations:
raw_author_name: Marlena Surowka
raw_affiliation_strings: Ludwig Maximilians University of Munich
Roche Innovation Center Zurich
Department of Biochemistry, Faculty of Chemistry and Pharmacy, Ludwig Maximilians University of Munich, Munich, Germany
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Diana Darowski
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Idil Hutter-Karakoc
raw_affiliation_strings: Roche Innovation Center Zurich
University of Zurich
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Christina Claus
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Claudia Ferrara-Koller
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Anne Freimoser-Grundschober
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Thomas Hofer
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Johannes Sam
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Reto Gianotti
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Andrzej Sobieniecki
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Denis Assisi
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: John Challier
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Stephane Leclair
raw_affiliation_strings: Roche Innovation Center Munich
Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
raw_author_name: Ekkehard Mössner
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Maria Amann
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Pablo Umaña
raw_affiliation_strings: Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
raw_author_name: Christian Klein
raw_affiliation_strings: Ludwig Maximilians University of Munich
Roche Innovation Center Zurich
Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
Department of Biochemistry, Faculty of Chemistry and Pharmacy, Ludwig Maximilians University of Munich, Munich, Germany